Retrospective Pathology Foundation Models
Development and Clinical Application of Deep Learning-Based Retrospective Pathology Foundation Models
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital, Southern Medical University
-
-
Shandong
-
Jinan, Shandong, China, 250014
- Qianfoshan Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 18-75 years old.
- Patients with complete pathological slides and clinical information.
Exclusion Criteria:
1.Patients with missing data or specimens not meeting quality control requirements for analysis.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
QFSH external validation dataset
1000 slides from 1000 eligible individuals were obtained in the Qianfoshan Hospital (QFSH, Jinan, China) between January 2020 and July 2025, which was used to validate the pathology foundation models.
|
|
NFH dataset
We conducted a validation study to compare the diagnostic performance among pathologists, our pathology foundation model, and pathologist-with-AI-assisted diagnosis.
This study was initiated at Nanfang Hospital, Southern Medical University (NFHSMU), with patient enrollment from January 1, 2011 to July 31, 2024.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under ROC curve (AUC)
Time Frame: Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
|
Area under the curve
|
Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Specificity
Time Frame: Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
|
The true negative rate (TNR) of the diagnostic platform, which is the ratio between the number of negative individuals correctly categorized by platform and the total number of actual negative individuals (%).
|
Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
|
|
Sensitivity
Time Frame: Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
|
The true positive rate (TPR) of the diagnostic platform, which is the ratio between the number of positive individuals correctly categorized by platform and the total number of actual positive individuals (%).
|
Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Li Liang, Nanfang Hospital, Southern Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- NFEC-2025-419
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.